330 related articles for article (PubMed ID: 7737328)
1. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
2. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
[TBL] [Abstract][Full Text] [Related]
3. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
4. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
5. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
6. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.
Tuomainen P; Törnwall M; Männistö PT
Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199
[TBL] [Abstract][Full Text] [Related]
7. Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
Okada M; Nakao R; Hosoi R; Zhang MR; Fukumura T; Suzuki K; Inoue O
J Cereb Blood Flow Metab; 2011 Jan; 31(1):124-31. PubMed ID: 20407462
[TBL] [Abstract][Full Text] [Related]
8. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
Törnwall M; Tuomainen P; Männistö PT
Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
[TBL] [Abstract][Full Text] [Related]
9. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
Huotari M; Gainetdinov R; Männistö PT
Pharmacol Toxicol; 1999 Nov; 85(5):233-8. PubMed ID: 10608486
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
[TBL] [Abstract][Full Text] [Related]
12. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Kaakkola S; Wurtman RJ
J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
[TBL] [Abstract][Full Text] [Related]
13. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
[TBL] [Abstract][Full Text] [Related]
14. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
[TBL] [Abstract][Full Text] [Related]
15. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
17. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.
Kaakkola S; Wurtman RJ
Brain Res; 1992 Aug; 587(2):241-9. PubMed ID: 1381981
[TBL] [Abstract][Full Text] [Related]
18. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
Steulet AF; Stöcklin K; Wicki P; Waldmeier P
Neurochem Res; 1993 Nov; 18(11):1131-6. PubMed ID: 8255364
[TBL] [Abstract][Full Text] [Related]
19. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation.
Raevskii KS; Gainetdinov RR; Budygin EA; Mannisto P; Wightman M
Neurosci Behav Physiol; 2002; 32(2):183-8. PubMed ID: 11942697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
